A Study of RO5036505 in Patients With Moderate to Severe Asthma
A Multi-center, Randomized, Double-Blind, Multiple-Dose, Placebo-controlled Asthma Control Study Evaluating the Efficacy, Safety, and Tolerability of RO5036505 in Subjects With Moderate-to-Severe Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hereford, United Kingdom, HR1 2ER
-
Manchester, United Kingdom, M23 9QZ
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
-
-
California
-
San Diego, California, United States, 92103
-
-
Colorado
-
Denver, Colorado, United States, 80206
-
-
Illinois
-
Normal, Illinois, United States, 61761
-
River Forest, Illinois, United States, 60305
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
-
-
Missouri
-
Saint Louis, Missouri, United States, 63130
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
-
Cleveland, Ohio, United States, 44195
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
-
-
Texas
-
Galveston, Texas, United States, 77555-0561
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients, 18-70 years of age
- moderate to severe asthma for >/=2 years
- ACQ score >/= 1.5
- ICS and LABA regimen at moderate to high dose
- non-smokers
Exclusion Criteria:
- oral corticosteroid use within 4 weeks prior to screening
- current escalating immunotherapy
- acute infection/antibiotic therapy within 4 weeks prior to screening, or chronic infection
- pulmonary disease other than asthma
- therapy with any approved monoclonal antibody or biologic agent within 12 months prior to screening
- previous exposure to investigational monoclonal antibodies or biologics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
380mg iv infusion once weekly for 8 weeks
|
|
Placebo Comparator: 2
|
iv infusion once weekly for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ACQ questionnaire, spirometry assessments, PEFR
Time Frame: every week up to day 95
|
every week up to day 95
|
|
Safety and tolerability: AEs, spirometry, concomitant medications, laboratory parameters
Time Frame: assessed every week, laboratory parameters every 3-4 weeks, up to day 95
|
assessed every week, laboratory parameters every 3-4 weeks, up to day 95
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics: AUC, Cmax, t1/2, V steady-state, clearance
Time Frame: sampling every week up to day 95
|
sampling every week up to day 95
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PP22666
- 2009-013379-23
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.